Humana (NYSE:HUM) Price Target Raised to $220.00

Humana (NYSE:HUM) had its price objective increased by Truist Financial from $200.00 to $220.00 in a report issued on Monday, Marketbeat.com reports. The firm currently has a hold rating on the insurance provider’s stock.

HUM has been the topic of a number of other research reports. Leerink Partners decreased their price target on shares of Humana from $267.00 to $185.00 and set a “market perform” rating on the stock in a research note on Thursday, February 12th. Evercore increased their target price on shares of Humana from $180.00 to $195.00 in a research report on Wednesday, April 8th. The Goldman Sachs Group decreased their target price on shares of Humana from $215.00 to $158.00 and set a “sell” rating on the stock in a research report on Friday, February 13th. Wolfe Research decreased their target price on shares of Humana from $325.00 to $250.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Finally, Royal Bank Of Canada lowered shares of Humana from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $322.00 to $189.00 in a research report on Thursday, February 12th. Seven research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $222.09.

Humana Stock Up 1.0%

Shares of HUM opened at $198.20 on Monday. Humana has a 52 week low of $163.11 and a 52 week high of $315.35. The firm has a market cap of $23.79 billion, a P/E ratio of 20.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.44. The firm’s 50-day simple moving average is $180.95 and its 200 day simple moving average is $231.53. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The business had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. During the same quarter in the prior year, the business earned ($2.16) EPS. Humana’s quarterly revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, analysts forecast that Humana will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, June 26th. Humana’s dividend payout ratio is presently 36.05%.

Insider Activity

In other Humana news, insider Sanjay K. Shetty bought 810 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were purchased at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the transaction, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by insiders.

Institutional Trading of Humana

Institutional investors and hedge funds have recently made changes to their positions in the company. Montag A & Associates Inc. lifted its holdings in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares during the period. CoreCap Advisors LLC lifted its holdings in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 37 shares during the period. Fideuram Asset Management Ireland dac bought a new stake in shares of Humana during the 4th quarter worth approximately $27,000. Reflection Asset Management bought a new stake in shares of Humana during the 4th quarter worth approximately $29,000. Finally, Rosenberg Matthew Hamilton lifted its holdings in shares of Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after acquiring an additional 68 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.